CD274 and non-small cell lung carcinoma: Our findings regarding median PFS and median OS are comparable with those recently reported by authors of a large multicenter Spanish nation-wide study that included 494 advanced NSCLC patients with PD-L1 TPS ≥ 50% that underwent pembrolizumab monotherapy in the first line of treatment [12].